Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAAM: Avastin and Macugen in AMD
NCT00531336Phase 2Completed
- Sponsor
- Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Start
- Jul 2006
- Primary completion
- Dec 2008
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, pegaptanib sodium in age-related macular degeneration (AMD), sponsored by Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Started Jul 2006; status: completed.
02
Drugs
bevacizumabpegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00531336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531336.